Precision Therapeutics, Inc., of Pittsburgh, will present pancreatic cancer data based on Precision's ChemoFx in-vitro chemosensitivity test at the 2011 American Society of Clinical Oncology (ASCO) GI Symposium in San Francisco

The study will be presented at the annual Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology

Analysts had been expecting a partnership for NKTR-102, particularly after the firm reported promising data at last year's American Society of Clinical Oncology meeting

Analysts and investors will have to wait until next year's American Society of Clinical Oncology meeting for detailed data, but there was no question Incyte execs were enthused

Regan said the firm plans to present the full efficacy and safety data at a "key" medical conference in the first half of 2011, with most analysts Tuesday predicting those presentations to occur at the annual meetings of the American Urological Association in Washington in May or the American Society of Clinical Oncology in Chicago in June

At the American Society of Clinical Oncology (ASCO) annual meeting in June, Celgene presented data from two Phase III trials of Revlimid maintenance therapy following autologous stem cell transplant

Despite the buzz XL184's GBM data generated at the American Society of Clinical Oncology meeting earlier this year, the company opted not to go further with that program

Beyond Zerenex, Keryx is keeping busy with another late-stage program, perifosine, a PI3K/Akt pathway inhibitor that captured attention at this year's American Society of Clinical Oncology meeting

Beyond Zerenex, Keryx is keeping busy with another late-stage program, perifosine, a PI3K/Akt pathway inhibitor that captured attention at this year's American Society of Clinical Oncology meeting

Shortly after Genentech presented the results of its Phase III ToGA study at the 2009 annual meeting of the American Society of Clinical Oncology, the National Comprehensive Cancer Network (NCCN) updated its clinical practice guidelines in oncology to include Herceptin as the recommended therapy for HER2-positive stomach cancer, Venook told BioWorld Today

The Cambridge, Mass.-based company presented its findings at a meeting of the American Society of Clinical Oncology (ASCO) Annual Molecular Markers in Cancer Conference on Oct. 18, 2010

OncoGenex is hoping the fast-tracked drug will confirm data seen in an earlier Phase II trial, which showed an overall survival benefit of 6.9 months over controls, wowing analysts at the 2009 American Society of Clinical Oncology meeting. (See BioWorld Today, June 2, 2009.) Back in June, OncoGenex and Jerusalem-based Teva kicked off the first Phase III study, which is designed to evaluate durable pain palliation as the primary endpoint

Celldex Therapeutics Inc., for example, had unveiled impressive Phase IIb data for brain cancer vaccine CDX-110 (rindopepimut) at the American Society of Clinical Oncology meeting only a few months before Pfizer Inc

Inc., attributed the sluggish third quarter follow-on performance to a stock dip in the wake of the American Society of Clinical Oncology (ASCO) annual meeting in June

Editor Despite the usual summer slowdown and some less-usual contributing factors, like a stock slump on the heels of the American Society of Clinical Oncology (ASCO) annual meeting in June, biotech fundraising continues to inch back from the brink

Still, Pfizer's decision, attributed to a reprioritization of the big pharma's pipeline, came only a few months after the firms unveiled impressive interim Phase IIb data at the American Society of Clinical Oncology meeting, showing that Celldex's EGFRvIII vaccine in combination with temozolomide produced a 70 percent progression-free survival rate at 5.5 months in patients with GBM

At the annual meeting in June of the American Society of Clinical Oncology (ASCO), BMS reported that patients given its investigational drug ipilimumab plus glycoprotein 100, a peptide vaccine, showed a median survival of 10 months, compared with 6.4 months for patients receiving the vaccine alone

In public comments from the American Society of Clinical Oncology, CEO Allen Lichter said his group was concerned that CMS may have plans to examine the issue of whether to cover Provenge for its FDA-approved indications

And the company anticipates moving into pivotal testing with AMG 479 in pancreatic cancer, following promising Phase II results from the insulin-like growth factor-targeted antibody reported at the American Society of Clinical Oncology meeting in June. (See BioWorld Today, June 7, 2010.) Shares of Amgen (NASDAQ:AMGN) closed Friday at $54.53, up $1.16.